Solventum SOLV plans to separate its Health Information Systems (HIS) business as part of its portfolio optimization strategy. The move is expected to sharpen the company’s focus on its core MedSurg and Dental Solutions businesses while allowing HIS to pursue its growth opportunities as a standalone entity.
From an investor perspective, the planned separation could unlock shareholder value by creating a more focused MedTech business and enabling targeted capital allocation toward Solventum’s higher-priority growth areas.
HIS, which generates $1.4 billion in annual sales and serves more than 75% of U.S. hospitals, could also benefit from greater strategic and financial flexibility. However, execution, regulatory approvals and uncertainty around the ultimate transaction structure remain key factors to watch.
Likely Trend of SOLV Stock Following the News
Shares of SOLV have gained almost 3% since the announcement of the news. In the year-to-date period, shares of the company have gained 9.1% compared with the industry’s 1.3% growth. The S&P 500 increased 12.8% in the same time frame.
The HIS business separation is likely to benefit Solventum’s long-term business by allowing it to operate as a more focused MedTech company centered on its MedSurg and Dental Solutions businesses. A streamlined portfolio should enable management to allocate capital more effectively toward higher-priority growth opportunities, accelerate innovation and improve commercial execution.
Meanwhile, separating HIS could reduce portfolio complexity and give Solventum greater flexibility to strengthen margins, enhance returns on invested capital and pursue strategic investments in its core businesses, potentially supporting a more sustainable growth profile over the long term.
SOLV currently has a market capitalization of $14.52 billion.
More on the News
Solventum’s planned separation of HIS marks the latest step in its three-phase transformation strategy and portfolio optimization efforts. The company expects the move to establish Solventum as a more focused MedTech player, with greater emphasis on its MedSurg and Dental Solutions businesses. HIS is a scaled healthcare software business with $1.4 billion in annual sales and operations across more than 30 countries. Its solutions are used by more than 75% of U.S. hospitals, supported by more than 40 years of medical coding expertise.
The business processes approximately 660 million clinical documents each month and provides revenue cycle management, performance management and clinician productivity solutions through long-term contracts and deeply embedded workflows. Operating in an estimated $10 billion addressable market growing 5-6% annually, HIS also benefits from proprietary technology, extensive data assets and AI-driven autonomous coding capabilities. As a standalone business, Solventum believes HIS could gain greater strategic focus, operational agility and capital allocation flexibility to expand autonomous coding adoption, enter international markets undergoing payment system modernization and pursue strategic partnerships and acquisitions.
The company aims to complete the separation within 12 to 18 months, although no final decision has been made regarding the structure or timing. Any potential transaction remains subject to approval by Solventum’s board of directors, regulatory requirements and other customary closing conditions. The company has also cautioned that there is no assurance that the separation will ultimately be completed and plans to provide updates as the process progresses.
Image Source: Zacks Investment Research
Solventum Advances Three-Phase Transformation Strategy
Solventum continues to make progress across all three phases of its transformation strategy, namely stabilizing and separating the business, repositioning it for profitable growth and optimizing the portfolio. The company is nearing completion of its separation from 3M, with nearly 70% of roughly 200 transition service agreements exited and about 950 of 1,200 systems migrated. Management expects to exit 90% of the agreements by year-end 2026, which should reduce complexity, free resources for growth initiatives and support margin expansion and free cash flow improvement.
The company continues to pursue disciplined tuck-in M&A, with Acera delivering more than 40% year-over-year revenue growth and gross margin above 80%. At the same time, Solventum is aligning innovation and commercial resources around five growth drivers that represent a multibillion-dollar opportunity, while expecting nearly 20 new product launches through the first quarter of 2028.
Management expects these initiatives to support stronger organic growth, margin expansion and shareholder value creation as the transformation progresses.
Recent Development by SOLV
Recently, Solventum delivered a strong second-quarter 2026, with earnings and revenues surpassing the Zacks Consensus Estimate. Performance benefited from healthy demand, new product launches and stronger commercial execution across all three segments. MedSurg gained from negative pressure wound therapy and antimicrobial IV-site management products. Dental Solutions benefited from restorative and aesthetics offerings, while HIS maintained momentum in revenue cycle management.
However, the reported growth rate was aided by approximately $125 million of advance orders ahead of ERP cutovers.
SOLV’s Zacks Rank & Key Picks
Currently, SOLV carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are McKesson MCK, Phibro Animal Health PAHC andCardinal Health CAH.
McKesson carries a Zacks Rank #2 (Buy) at present and has an estimated long-term growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.09%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
McKessonshares have gained 8.8% against the industry’s 12.7% decline in the year-to-date period.
Phibro Animal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.25%.
Phibro Animal Health stock has climbed 44.2% against the industry’s 17.1% decline in the year-to-date period.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.
Cardinal Health’s shares have lost 2.6% compared with the industry’s 3.1% decline in the year-to-date period.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.Â
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Â
Â
Â
Â
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.